Moderna

YTD

ALL

Trade Moderna 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRNA

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics.

CEO

Stéphane Bancel

CEOStéphane Bancel

Employees

4,700

Employees4,700

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

2010

Founded2010

Employees

4,700

Employees4,700

MRNA Key Statistics

Market cap

31.65B

Market cap31.65B

Price-Earnings ratio

-9.79

Price-Earnings ratio-9.79

Dividend yield

—

Dividend yield—

Average volume

11.55M

Average volume11.55M

High today

$81.40

High today$81.40

Low today

$72.65

Low today$72.65

Open price

$73.75

Open price$73.75

Volume

14.11M

Volume14.11M

52 Week high

$81.40

52 Week high$81.40

52 Week low

$22.28

52 Week low$22.28

Stock Snapshot

As of today, Moderna(MRNA) shares are valued at $80.42. The company's market cap stands at 31.65B, with a P/E ratio of -9.79.

As of 2026-07-06, Moderna(MRNA) stock has fluctuated between $72.65 and $81.40. The current price stands at $80.42, placing the stock +10.7% above today's low and -1.2% off the high.

The Moderna(MRNA)'s current trading volume is 14.11M, compared to an average daily volume of 11.55M.

During the past year, Moderna(MRNA) stock moved between $22.28 at its lowest and $81.40 at its peak.

MRNA News

Simply Wall St 2d

Can Moderna Justify Its Valuation On FDA Flu Backing And Science Day Updates?

Moderna (MRNA) is back in focus after a key FDA advisory committee unanimously backed its mRNA-based flu vaccine, mFlusiva, and the company used its Science Day...

TipRanks 2d

Moderna’s Pipeline Hype Sends Shares Soaring Again

Moderna ( (MRNA) ) has risen by 14.43%. Read on to learn why. 4th of July Sale - 70% Off Unlock powerful investing tools and data-driven insights with TipRanks...

Nasdaq 2d

Moderna Is Up More Than 70% in a Month After a 9-0 FDA Vote. Wall Street's Average Price Target Says It Should Fall 44%. What Gives?

Key Points An FDA advisory panel voted 9-0 that Moderna's mRNA flu vaccine's benefits outweigh its risks. A final approval decision is expected by Aug. 5. Th...

Analyst ratings

67%

of 27 ratings

Buy

14.8%

Hold

66.7%

Sell

18.5%

More MRNA News

Nasdaq 3d

Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?

Key Points Moderna is evolving from a COVID-19 vaccine specialist into a multi-product firm with major oncology and rare disease partnerships. Recursion Pharm...

Simply Wall St 4d

Moderna Is Up 14.8% After FDA Panel Backs mRNA Flu Shot mFlusiva Approval – Has The Bull Case Changed?

In June 2026, a key FDA advisory committee unanimously recommended approval of Moderna’s mRNA-based influenza vaccine, mFlusiva (mRNA-1010), for adults aged 50...

Zacks 7d

MRNA Stock Jumps to 52-Week High on Expansion Plans Beyond Vaccines - Zacks Investment Research

...

People also own

Based on the portfolios of people who own MRNA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.